Google NewsLTR Pharma (ASX:LTP) Rises As US Commercial Pathway Expands - Kalkine
LTR Pharma (ASX:LTP) Rises As US Commercial Pathway Expands Kalkine
Ltr Pharma (LTP) News
Latest articles and price-sensitive announcements with AI sentiment classification.
LTR Pharma (ASX:LTP) posts 93% response in 147-patient SPONTAN study as US launch nears - Stocks Down Under
LTR Pharma (ASX:LTP) posts 93% response in 147-patient SPONTAN study as US launch nears Stocks Down Under
ASXQuarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why LTR Pharma (ASX:LTP) Shares Are in Focus After a Key U.S. Agreement? - Kalkine
Why LTR Pharma (ASX:LTP) Shares Are in Focus After a Key U.S. Agreement? Kalkine
LTR Executes U.S. Commercial Agreement with Strive
other announcement
LTR Executes Definitive U.S. Commercial Agreement with Shed
other announcement
Notification regarding unquoted securities - LTP
other announcement
Is LTR Pharma (ASX: LTP) Losing Momentum After a Strong One-Year Gain? - Kalkine
Is LTR Pharma (ASX: LTP) Losing Momentum After a Strong One-Year Gain? Kalkine
LTR Pharma (ASX:LTP) in Focus as Speculative Interest Shifts - Kalkine
LTR Pharma (ASX:LTP) in Focus as Speculative Interest Shifts Kalkine
Linius Technologies (ASX: LTP) Sparks Fresh Tech Buzz as AI Video and Digital Media Themes Build - Kalkine
Linius Technologies (ASX: LTP) Sparks Fresh Tech Buzz as AI Video and Digital Media Themes Build Kalkine
LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
other announcement
LTR Secures First U.S. Commercial Agreement for ROXUS
other announcement
SPONTAN Phase II data show rapid onset, support FDA pathway
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
SPONTAN Phase II Clinical Study Completes Recruitment
other announcement
SPONTAN Shows Positive Outcomes in Younger Men with ED
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
First Patients Dosed in SPONTAN Phase II Clinical Study
other announcement
Notification regarding unquoted securities - LTP
other announcement
Patient Recruitment Commences for SPONTAN Phase II Study
other announcement
SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium
other announcement
Notification regarding unquoted securities - LTP
other announcement
LTR Pharma Surpasses 1,000 SPONTAN Prescriptions
other announcement
TGA Provides Regulatory Clearance for SPONTAN Phase II
other announcement
Ethics Approval Received for SPONTAN Phase II Clinical Study
other announcement
Release of Restricted Securities from ASX Mandatory Escrow
other announcement
Change of Director's Interest Notice - M McGuire
director_dealing announcement
Change of Director's Interest Notice - J Chick
director_dealing announcement
Change of Director's Interest Notice - L Rodne
director_dealing announcement
Notification regarding unquoted securities - LTP
other announcement
Notification regarding unquoted securities - LTP
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
LTR increases LevOmega stake to 43% with $1m investment
other announcement
LTR Pharma secures 33% ownership in LevOmega Pty Ltd
other announcement
SPONTAN Case Series - Strong Post-Prostatectomy Results
other announcement
18-Month Shelf Life Strengthens SPONTAN Commercialisation
other announcement
US ED Specialist Dr Sun Joins LTR Advisory Board
other announcement
US ED Specialist Dr Pearlman Joins LTR Advisory Board
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement